Precision BioSciences Stock (NASDAQ:DTIL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$9.02

52W Range

$7.97 - $19.43

50D Avg

$9.37

200D Avg

$10.86

Market Cap

$59.97M

Avg Vol (3M)

$59.81K

Beta

1.68

Div Yield

-

DTIL Company Profile


Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

110

IPO Date

Mar 28, 2019

Website

DTIL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 21Dec 20Dec 19
Therapeutics Segment$111.72M$21.86M$20.63M
Food Segment$3.81M$2.42M$1.61M

Fiscal year ends in Dec 23 | Currency in USD

DTIL Financial Summary


Dec 23Dec 22Dec 21
Revenue$48.73M$25.10M$115.53M
Operating Income$-42.53M$-100.37M$-39.40M
Net Income$-61.32M$-122.91M$-30.92M
EBITDA$-42.53M$-98.47M$-28.81M
Basic EPS$-0.02$-1.40$-0.53
Diluted EPS$-0.02$-1.40$-0.53

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
DYNDyne Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
MREOMereo BioPharma Group plc
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
ALECAlector, Inc.
HOOKHOOKIPA Pharma Inc.
BDTXBlack Diamond Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
PASGPassage Bio, Inc.
INZYInozyme Pharma, Inc.
ELDNEledon Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
CYTKCytokinetics, Incorporated